Table of Contents Author Guidelines Submit a Manuscript
Oxidative Medicine and Cellular Longevity
Volume 2016 (2016), Article ID 8590578, 15 pages
http://dx.doi.org/10.1155/2016/8590578
Review Article

The Role of Reactive Oxygen Species in the Pathogenesis of Alzheimer’s Disease, Parkinson’s Disease, and Huntington’s Disease: A Mini Review

1Department of Biochemistry and Biotechnology, Faculty of Science, Annamalai University, Annamalainagar, Tamil Nadu, India
2Neuroinflammation Group, Department of Biomedical Research, Faculty of Medicine and Health Sciences, Macquarie University, Sydney, NSW, Australia
3Department of Food Science and Nutrition, Sultan Qaboos University, Muscat, Oman
4SMPT, NIAAA, National Institutes of Health, Rockville, MD, USA

Received 8 July 2016; Revised 6 October 2016; Accepted 13 November 2016

Academic Editor: Rodrigo Franco

Copyright © 2016 Shanmugam Manoharan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. B. Uttara, A. V. Singh, P. Zamboni, and R. T. Mahajan, “Oxidative stress and neurodegenerative diseases: a review of upstream and downstream antioxidant therapeutic options,” Current Neuropharmacology, vol. 7, no. 1, pp. 65–74, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. M. N. Rossor, N. C. Fox, C. J. Mummery, J. M. Schott, and J. D. Warren, “The diagnosis of young-onset dementia,” The Lancet Neurology, vol. 9, no. 8, pp. 793–806, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. M. T. Lin and M. F. Beal, “Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases,” Nature, vol. 443, pp. 787–795, 2006. View at Publisher · View at Google Scholar · View at Scopus
  4. D. A. Butterfield and D. Boyd-Kimball, “Amyloid β-peptide(1-42) contributes to the oxidative stress and neurodegeneration found in Alzheimer disease brain,” Brain Pathology, vol. 14, no. 4, pp. 426–432, 2004. View at Google Scholar · View at Scopus
  5. C. A. Lemere and E. Masliah, “Can Alzheimer disease be prevented by amyloid-β immunotherapy?” Nature Reviews Neurology, vol. 6, no. 2, pp. 108–119, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. L. Mosconi, A. Pupi, and M. J. De Leon, “Brain glucose hypometabolism and oxidative stress in preclinical Alzheimer's disease,” Annals of the New York Academy of Sciences, vol. 1147, pp. 180–195, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. C. P. Ferri, M. Prince, C. Brayne et al., “Global prevalence of dementia: a Delphi consensus study,” The Lancet, vol. 366, no. 9503, pp. 2112–2117, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. D. Praticò, “Evidence of oxidative stress in Alzheimer's disease brain and antioxidant therapy: lights and shadows,” Annals of the New York Academy of Sciences, vol. 1147, pp. 70–78, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. F. P. Joseph, C. Darrell Jennings, J. K. Richard et al., “Association of HFE mutations with neurodegeneration and oxidative stress in Alzheimer's disease and correlation with APOE,” American Journal of Medical Genetics, vol. 119, pp. 48–53, 2003. View at Google Scholar
  10. T. D. Bird, “Genetic aspects of Alzheimer disease,” Genetics in Medicine, vol. 10, no. 4, pp. 231–239, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. E. H. Verbon, J. A. Post, and J. Boonstra, “The influence of reactive oxygen species on cell cycle progression in mammalian cells,” Gene, vol. 511, no. 1, pp. 1–6, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. Y. Son, S. Kim, H.-T. Chung, and H.-O. Pae, “Reactive oxygen species in the activation of MAP kinases,” Methods in Enzymology, vol. 528, pp. 27–48, 2013. View at Publisher · View at Google Scholar · View at Scopus
  13. G. A. Knock and J. P. T. Ward, “Redox regulation of protein kinases as a modulator of vascular function,” Antioxidants and Redox Signaling, vol. 15, no. 6, pp. 1531–1547, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. M. Lo Conte and K. S. Carroll, “The redox biochemistry of protein sulfenylation and sulfinylation,” The Journal of Biological Chemistry, vol. 288, no. 37, pp. 26480–26488, 2013. View at Publisher · View at Google Scholar · View at Scopus
  15. X. Chen, C. Guo, and J. Kong, “Oxidative stress in neurodegenerative diseases,” Neural Regeneration Research, vol. 7, no. 5, pp. 376–385, 2012. View at Google Scholar · View at Scopus
  16. Z. Xie, M. Wei, T. E. Morgan et al., “Peroxynitrite mediates neurotoxicity of amyloid beta-peptide1-42- and lipopolysaccharide-activated microglia,” The Journal of Neuroscience, vol. 22, no. 9, pp. 3484–3492, 2002. View at Google Scholar · View at Scopus
  17. K. Van Dyke, “The possible role of peroxynitrite in Alzheimer's disease: a simple hypothesis that could be tested more thoroughly,” Medical Hypotheses, vol. 48, no. 5, pp. 375–380, 1997. View at Publisher · View at Google Scholar · View at Scopus
  18. K. Nakajima and S. Kohsaka, “Microglia: activation and their significance in the central nervous system,” Journal of Biochemistry, vol. 130, no. 2, pp. 169–175, 2001. View at Publisher · View at Google Scholar · View at Scopus
  19. J. Friedman, “Why is the nervous system vulnerable to oxidative stress?” in Oxidative Stress in Applied Basic Research and Clinical Practice, N. Gadoth and H. H. Göbel, Eds., pp. 19–27, Humana Press, Totowa, NJ, USA, 2011. View at Publisher · View at Google Scholar
  20. E. Munkácsy and S. L. Rea, “The paradox of mitochondrial dysfunction and extended longevity,” Experimental Gerontology, vol. 56, pp. 221–233, 2014. View at Publisher · View at Google Scholar · View at Scopus
  21. S. M. Yatin, M. Yatin, T. Aulick, K. B. Ain, and D. A. Butterfield, “Alzheimer's amyloid β-peptide associated free radicals increase rat embryonic neuronal polyamine uptake and ornithine decarboxylase activity: protective effect of vitamin E,” Neuroscience Letters, vol. 263, no. 1, pp. 17–20, 1999. View at Publisher · View at Google Scholar · View at Scopus
  22. D. A. Butterfield and C. M. Lauderback, “Lipid peroxidation and protein oxidation in Alzheimer's disease brain: potential causes and consequences involving amyloid β-peptide-associated free radical oxidative stress,” Free Radical Biology and Medicine, vol. 32, no. 11, pp. 1050–1060, 2002. View at Publisher · View at Google Scholar · View at Scopus
  23. J. Drake, C. D. Link, and D. A. Butterfield, “Oxidative stress precedes fibrillar deposition of Alzheimer's disease amyloid β-peptide (1–42) in a transgenic Caenorhabditis elegans model,” Neurobiology of Aging, vol. 24, no. 3, pp. 415–420, 2003. View at Publisher · View at Google Scholar · View at Scopus
  24. C. A. Massaad, “Neuronal and vascular oxidative stress in Alzheimer's disease,” Current Neuropharmacology, vol. 9, no. 4, pp. 662–673, 2011. View at Publisher · View at Google Scholar · View at Scopus
  25. I. Baldeiras, I. Santana, M. T. Proença et al., “Peripheral oxidative damage in mild cognitive impairment and mild Alzheimer's disease,” Journal of Alzheimer's Disease, vol. 15, no. 1, pp. 117–128, 2008. View at Google Scholar · View at Scopus
  26. J. Greilberger, C. Koidl, M. Greilberger et al., “Malondialdehyde, carbonyl proteins and albumin-disulphide as useful oxidative markers in mild cognitive impairment and Alzheimer's disease,” Free Radical Research, vol. 42, no. 7, pp. 633–638, 2008. View at Publisher · View at Google Scholar · View at Scopus
  27. A. M. Palmer and M. A. Burns, “Selective increase in lipid peroxidation in the inferior temporal cortex in Alzheimer's disease,” Brain Research, vol. 645, no. 1-2, pp. 338–342, 1994. View at Publisher · View at Google Scholar · View at Scopus
  28. M. A. Lovell, W. D. Ehmann, S. M. Butler, and W. R. Markesbery, “Elevated thiobarbituric acid-reactive substances and antioxidant enzyme activity in the brain in Alzheimer's disease,” Neurology, vol. 45, no. 8, pp. 1594–1601, 1995. View at Publisher · View at Google Scholar · View at Scopus
  29. D. L. Marcus, C. Thomas, C. Rodriguez et al., “Increased peroxidation and reduced antioxidant enzyme activity in Alzheimer's disease,” Experimental Neurology, vol. 150, no. 1, pp. 40–44, 1998. View at Publisher · View at Google Scholar · View at Scopus
  30. S. P. Gabbita, M. A. Lovell, and W. R. Markesbery, “Increased nuclear DNA oxidation in the brain in Alzheimer' s disease,” Journal of Neurochemistry, vol. 71, no. 5, pp. 2034–2040, 1998. View at Google Scholar · View at Scopus
  31. K. Hensley, N. Hall, R. Subramaniam et al., “Brain regional correspondence between Alzheimer's disease histopathology and biomarkers of protein oxidation,” Journal of Neurochemistry, vol. 65, no. 5, pp. 2146–2156, 1995. View at Google Scholar · View at Scopus
  32. M. A. Smith, P. L. R. Harris, L. M. Sayre, and G. Perry, “Iron accumulation in Alzheimer disease is a source of redox-generated free radicals,” Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 18, pp. 9866–9868, 1997. View at Publisher · View at Google Scholar · View at Scopus
  33. M. A. Lovell, J. D. Robertson, W. J. Teesdale, J. L. Campbell, and W. R. Markesbery, “Copper, iron and zinc in Alzheimer's disease senile plaques,” Journal of the Neurological Sciences, vol. 158, no. 1, pp. 47–52, 1998. View at Publisher · View at Google Scholar · View at Scopus
  34. G. Casadesus, M. A. Smith, X. Zhu et al., “Alzheimer disease: evidence for a central pathogenic role of iron-mediated reactive oxygen species,” Journal of Alzheimer's Disease, vol. 6, no. 2, pp. 165–169, 2004. View at Google Scholar · View at Scopus
  35. C. A. Rottkamp, A. K. Raina, X. Zhu et al., “Redox-active iron mediates amyloid-β toxicity,” Free Radical Biology and Medicine, vol. 30, no. 4, pp. 447–450, 2001. View at Publisher · View at Google Scholar
  36. M. J. Rowan, I. Klyubin, Q. Wang, and R. Anwyl, “Mechanisms of the inhibitory effects of amyloid β-protein on synaptic plasticity,” Experimental Gerontology, vol. 39, no. 11-12, pp. 1661–1667, 2004. View at Publisher · View at Google Scholar · View at Scopus
  37. E. Karelson, N. Bogdanovic, A. Garlind et al., “The cerebrocortical areas in normal brain aging and in Alzheimer's disease: noticeable differences in the lipid peroxidation level and in antioxidant defense,” Neurochemical Research, vol. 26, no. 4, pp. 353–361, 2001. View at Publisher · View at Google Scholar · View at Scopus
  38. R. Castellani, K. Hirai, G. Aliev et al., “Role of mitochondrial dysfunction in Alzheimer's disease,” Journal of Neuroscience Research, vol. 70, no. 3, pp. 357–360, 2002. View at Publisher · View at Google Scholar · View at Scopus
  39. G. E. Gibson, K.-F. R. Sheu, and J. P. Blass, “Abnormalities of mitochondrial enzymes in Alzheimer disease,” Journal of Neural Transmission, vol. 105, no. 8-9, pp. 855–870, 1998. View at Publisher · View at Google Scholar · View at Scopus
  40. S. M. Yatin, S. Varadarajan, and D. A. Butterfield, “Vitamin E prevents Alzheimer's amyloid β-peptide (1-42)-induced neuronal protein oxidation and reactive oxygen species production,” Journal of Alzheimer's Disease, vol. 2, no. 2, pp. 123–131, 2000. View at Google Scholar · View at Scopus
  41. A. Y. Abramov, L. Canevari, and M. R. Duchen, “Changes in intracellular calcium and glutathione in astrocytes as the primary mechanism of amyloid neurotoxicity,” Journal of Neuroscience, vol. 23, no. 12, pp. 5088–5095, 2003. View at Google Scholar · View at Scopus
  42. J. B. Melo, P. Agostinho, and C. R. Oliveira, “Involvement of oxidative stress in the enhancement of acetylcholinesterase activity induced by amyloid beta-peptide,” Neuroscience Research, vol. 45, no. 1, pp. 117–127, 2003. View at Publisher · View at Google Scholar · View at Scopus
  43. K. Rahman, “Studies on free radicals, antioxidants, and co-factors,” Clinical Interventions in Aging, vol. 2, no. 2, pp. 219–236, 2007. View at Google Scholar · View at Scopus
  44. A. Singhal, O. Bangar, and V. Naithani, “Medicinal plants with a potential to treat Alzheimer and associated symptoms,” International Journal of Nutrition, Pharmacology, Neurological Diseases, vol. 2, no. 2, pp. 84–91, 2012. View at Publisher · View at Google Scholar
  45. P. Upadhyay, D. Panjwani, and A. K. Yadav, “Neuropathology staging and treatment strategies of Alzheimer's disease: an update,” International Journal of Nutrition, Pharmacology, Neurological Diseases, vol. 4, no. 1, pp. 28–42, 2014. View at Publisher · View at Google Scholar
  46. G. H. Kim, J. E. Kim, S. J. Rhie, and S. Yoon, “The role of oxidative stress in neurodegenerative diseases,” Experimental Neurobiology, vol. 24, no. 4, pp. 325–340, 2015. View at Publisher · View at Google Scholar
  47. M. R. Ven Murthy, P. K. Ranjekar, C. Ramassamy, and M. Deshpande, “Scientific basis for the use of Indian ayurvedic medicinal plants in the treatment of neurodegenerative disorders: 1. Ashwagandha,” Central Nervous System Agents in Medicinal Chemistry, vol. 10, no. 3, pp. 238–246, 2010. View at Publisher · View at Google Scholar · View at Scopus
  48. M. H. Veerendra Kumar and Y. K. Gupta, “Effect of Centella asiatica on cognition and oxidative stress in an intracerebroventricular streptozotocin model of Alzheimer's disease in rats,” Clinical and Experimental Pharmacology and Physiology, vol. 30, no. 5-6, pp. 336–342, 2003. View at Publisher · View at Google Scholar · View at Scopus
  49. M. Dhanasekaran, L. A. Holcomb, A. R. Hitt et al., “Centella asiatica extract selectively decreases amyloid β levels in hippocampus of alzheimer's disease animal model,” Phytotherapy Research, vol. 23, no. 1, pp. 14–19, 2009. View at Publisher · View at Google Scholar · View at Scopus
  50. M. E. Clementi, G. Tringali, D. Triggiani, and B. Giardina, “Aloe arborescens extract protects IMR-32 Cells against Alzheimer amyloid beta peptide via inhibition of radical peroxide production,” Natural Product Communications, vol. 10, no. 11, pp. 1993–1995, 2015. View at Google Scholar · View at Scopus
  51. Y.-S. Gong, J. Guo, K. Hu et al., “Ameliorative effect of lotus seedpod proanthocyanidins on cognitive impairment and brain aging induced by D-galactose,” Experimental Gerontology, vol. 74, pp. 21–28, 2016. View at Publisher · View at Google Scholar · View at Scopus
  52. N. H. Turgut, H. Kara, E. Arslanbaş, D. G. Mert, B. Tepe, and H. Güngör, “Effect of Capparis spinosa L. On cognitive impairment induced by D-galactose in mice via inhibition of oxidative stress,” Turkish Journal of Medical Sciences, vol. 45, no. 5, pp. 1127–1136, 2015. View at Publisher · View at Google Scholar · View at Scopus
  53. X.-L. Yu, Y.-N. Li, H. Zhang et al., “Rutin inhibits amylin-induced neurocytotoxicity and oxidative stress,” Food and Function, vol. 6, no. 10, pp. 3296–3306, 2015. View at Publisher · View at Google Scholar · View at Scopus
  54. N. Mairuae, J. R. Connor, S. Y. Lee, P. Cheepsunthorn, and W. Tongjaroenbuangam, “The effects of okra (Abelmoschus esculentus Linn.) on the cellular events associated with Alzheimer's disease in a stably expressed HFE neuroblastoma SH-SY5Y cell line,” Neuroscience Letters, vol. 31, no. 603, pp. 6–11, 2015. View at Publisher · View at Google Scholar · View at Scopus
  55. M. N. Uddin, R. Afrin, M. J. Uddin et al., “Vanda roxburghii chloroform extract as a potential source of polyphenols with antioxidant and cholinesterase inhibitory activities: identification of a strong phenolic antioxidant,” BMC Complementary and Alternative Medicine, vol. 15, no. 1, article 195, 2015. View at Publisher · View at Google Scholar · View at Scopus
  56. M. Barbagallo, F. Marotta, and L. J. Dominguez, “Oxidative stress in patients with Alzheimer's disease: effect of extracts of fermented papaya powder,” Mediators of Inflammation, vol. 2015, Article ID 624801, 6 pages, 2015. View at Publisher · View at Google Scholar · View at Scopus
  57. K. Lu, C. Zhang, W. Wu, M. Zhou, Y. Tang, and Y. Peng, “Rhubarb extract has a protective role against radiation-induced brain injury and neuronal cell apoptosis,” Molecular Medicine Reports, vol. 12, no. 2, pp. 2689–2694, 2015. View at Publisher · View at Google Scholar
  58. S. Giacoppo, M. Galuppo, S. Montaut et al., “An overview on neuroprotective effects of isothiocyanates for the treatment of neurodegenerative diseases,” Fitoterapia, vol. 106, pp. 12–21, 2015. View at Publisher · View at Google Scholar · View at Scopus
  59. L. Zhao, S. Liu, Y. Wang et al., “Effects of curculigoside on memory impairment and bone loss via anti-oxidative character in APP/PS1 mutated transgenic mice,” PLoS ONE, vol. 10, no. 7, Article ID e0133289, 2015. View at Publisher · View at Google Scholar · View at Scopus
  60. B. Muthaiyah, M. M. Essa, V. Chauhan, and A. Chauhan, “Protective effects of walnut extract against amyloid beta peptide-induced cell death and oxidative stress in PC12 cells,” Neurochemical Research, vol. 36, no. 11, pp. 2096–2103, 2011. View at Publisher · View at Google Scholar · View at Scopus
  61. R. E. Hartman, A. Shah, A. M. Fagan et al., “Pomegranate juice decreases amyloid load and improves behavior in a mouse model of Alzheimer's disease,” Neurobiology of Disease, vol. 24, no. 3, pp. 506–515, 2006. View at Publisher · View at Google Scholar · View at Scopus
  62. S. Subash, M. M. Essa, A. Al-Asmi, S. Al-Adawi, R. Vaishnav, and G. J. Guillemin, “Effect of dietary supplementation of dates in Alzheimer’s disease APPsw/2576 transgenic mice on oxidative stress and antioxidant status,” Nutritional Neuroscience, vol. 18, no. 6, pp. 281–288, 2015. View at Publisher · View at Google Scholar · View at Scopus
  63. A. Nakajima, Y. Aoyama, E.-J. Shin et al., “Nobiletin, a citrus flavonoid, improves cognitive impairment and reduces soluble Aβ levels in a triple transgenic mouse model of Alzheimer's disease (3XTg-AD),” Behavioural Brain Research, vol. 289, pp. 69–77, 2015. View at Publisher · View at Google Scholar · View at Scopus
  64. A. Sun, X. Xu, J. Lin, X. Cui, and R. Xu, “Neuroprotection by saponins,” Phytotherapy Research, vol. 29, no. 2, pp. 187–200, 2015. View at Publisher · View at Google Scholar
  65. J. R. P. Prasanthi, B. Dasari, G. Marwarha et al., “Caffeine protects against oxidative stress and Alzheimer's disease-like pathology in rabbit hippocampus induced by cholesterol-enriched diet,” Free Radical Biology and Medicine, vol. 49, no. 7, pp. 1212–1220, 2010. View at Publisher · View at Google Scholar · View at Scopus
  66. D. Boyd-Kimball, R. Sultana, H. Mohmmad Abdul, and D. A. Butterfield, “γ-glutamylcysteine ethyl ester-induced up-regulation of glutathione protects neurons against Aβ(1-42)-mediated oxidative stress and neurotoxicity: implications for Alzheimer's disease,” Journal of Neuroscience Research, vol. 79, no. 5, pp. 700–706, 2005. View at Publisher · View at Google Scholar · View at Scopus
  67. J. C. Hanish Singh, V. Alagarsamy, S. Sathesh Kumar, and Y. Narsimha Reddy, “Neurotransmitter metabolic enzymes and antioxidant status on Alzheimer's disease induced mice treated with Alpinia galanga (L.) Willd,” Phytotherapy Research, vol. 25, no. 7, pp. 1061–1067, 2011. View at Publisher · View at Google Scholar · View at Scopus
  68. M. Akbar, B.-J. Song, M. M. Essa, and M. A. Khan, “Pomegranate: an ideal fruit for human health,” International Journal of Nutrition, Pharmacology, Neurological Diseases, vol. 5, no. 4, pp. 141–143, 2015. View at Publisher · View at Google Scholar · View at Scopus
  69. S. Subash, M. M. Essa, N. Braidy et al., “Diet rich in date palm fruits improves memory, learning and reduces beta amyloid in transgenic mouse model of Alzheimer's disease,” Journal of Ayurveda and Integrative Medicine, vol. 6, no. 2, pp. 111–120, 2015. View at Publisher · View at Google Scholar · View at Scopus
  70. S. Subash, N. Braidy, M. M. Essa et al., “Long-term (15 mo) dietary supplementation with pomegranates from Oman attenuates cognitive and behavioral deficits in a transgenic mice model of Alzheimer's disease,” Nutrition, vol. 31, no. 1, pp. 223–229, 2015. View at Publisher · View at Google Scholar · View at Scopus
  71. S. Subash, M. Essa, A. Al-Asmi et al., “Pomegranate from oman alleviates the brain oxidative damage in transgenic mouse model of alzheimer′s disease,” Journal of Traditional and Complementary Medicine, vol. 4, no. 4, pp. 232–238, 2014. View at Publisher · View at Google Scholar · View at Scopus
  72. S. Subash, M. M. Essa, S. Al-Adawi, M. A. Memon, T. Manivasagam, and M. Akbar, “Neuroprotective effects of berry fruits on neurodegenerative diseases,” Neural Regeneration Research, vol. 9, no. 16, pp. 1557–1566, 2014. View at Publisher · View at Google Scholar · View at Scopus
  73. S. Subash, M. M. Essa, A. Al-Asmi, S. Al-Adawi, and R. Vaishnav, “Chronic dietary supplementation of 4% figs on the modification of oxidative stress in Alzheimer's disease transgenic mouse model,” BioMed Research International, vol. 2014, Article ID 546357, 8 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus
  74. S. Subash, M. M. Essa, N. Braidy et al., “Consumption of fig fruits grown in Oman can improve memory, anxiety, and learning skills in a transgenic mice model of Alzheimer's disease,” Nutritional Neuroscience, vol. 19, no. 10, pp. 475–483, 2016. View at Publisher · View at Google Scholar
  75. M. M. Essa, S. Subash, C. Dhanalakshmi et al., “Dietary supplementation of walnut partially reverses 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine induced neurodegeneration in a mouse model of Parkinson’s disease,” Neurochemical Research, vol. 40, no. 6, pp. 1283–1293, 2015. View at Publisher · View at Google Scholar · View at Scopus
  76. M. M. Essa, S. Subash, M. Akbar, S. Al-Adawi, and G. J. Guillemin, “Long-Term dietary supplementation of pomegranates, figs and dates alleviate neuroinflammation in a transgenic mouse model of alzheimer's disease,” PLOS ONE, vol. 25, no. 10, Article ID e0120964, 2015. View at Publisher · View at Google Scholar · View at Scopus
  77. B. Muthaiyah, M. M. Essa, M. Lee, V. Chauhan, K. Kaur, and A. Chauhan, “Dietary supplementation of walnuts improves memory deficits and learning skills in transgenic mouse model of Alzheimer's disease,” Journal of Alzheimer's Disease, vol. 42, no. 4, pp. 1397–1405, 2014. View at Publisher · View at Google Scholar · View at Scopus
  78. M. M. Goldenberg, “Medical management of Parkinson's disease,” P and T, vol. 33, no. 10, pp. 590–606, 2008. View at Google Scholar · View at Scopus
  79. G. DeMaagd and A. Philip, “Parkinson's disease and its management: part 1: disease entity, risk factors, pathophysiology, clinical presentation, and diagnosis,” Pharmacy and Therapeutics, vol. 40, no. 8, pp. 504–532, 2015. View at Google Scholar
  80. J. Massano and K. P. Bhatia, “Clinical approach to Parkinson's disease: features, diagnosis, and principles of management,” Cold Spring Harbor Perspectives in Medicine, vol. 2, no. 6, Article ID a008870, 2012. View at Publisher · View at Google Scholar · View at Scopus
  81. J. B. Leverenz, J. F. Quinn, C. Zabetian, J. Zhang, K. S. Montine, and T. J. Montine, “Cognitive impairment and dementia in patients with Parkinson disease,” Current Topics in Medicinal Chemistry, vol. 9, no. 10, pp. 903–912, 2009. View at Publisher · View at Google Scholar · View at Scopus
  82. J. M. Savitt, V. L. Dawson, and T. M. Dawson, “Diagnosis and treatment of Parkinson disease: molecules to medicine,” Journal of Clinical Investigation, vol. 116, no. 7, pp. 1744–1754, 2006. View at Publisher · View at Google Scholar · View at Scopus
  83. W. D. Parker Jr., J. K. Parks, and R. H. Swerdlow, “Complex I deficiency in Parkinson's disease frontal cortex,” Brain Research, vol. 1189, pp. 215–218, 2008. View at Publisher · View at Google Scholar · View at Scopus
  84. G. E. Alexander, “Biology of Parkinson's disease: pathogenesis and pathophysiology of a multisystem neurodegenerative disorder,” Dialogues in Clinical Neuroscience, vol. 6, no. 3, pp. 259–280, 2004. View at Google Scholar · View at Scopus
  85. S. Sarkar, J. Raymick, and S. Imam, “Neuroprotective and therapeutic strategies against Parkinson’s disease: recent perspectives,” International Journal of Molecular Sciences, vol. 17, no. 6, article no. 904, 2016. View at Publisher · View at Google Scholar
  86. R. L. Albin, “Parkinson's disease: background, diagnosis, and initial management,” Clinics in Geriatric Medicine, vol. 22, no. 4, pp. 735–751, 2006. View at Publisher · View at Google Scholar · View at Scopus
  87. E. R. Dorsey, R. Constantinescu, J. P. Thompson et al., “Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030,” Neurology, vol. 68, no. 5, pp. 384–386, 2007. View at Publisher · View at Google Scholar · View at Scopus
  88. J. Hardy, “Genetic analysis of pathways to parkinson disease,” Neuron, vol. 68, no. 2, pp. 201–206, 2010. View at Publisher · View at Google Scholar · View at Scopus
  89. A. L. Friedlich, M. A. Smith, X. Zhu et al., “Oxidative stress in Parkinson's disease,” The Open Pathology Journal, vol. 3, no. 1, pp. 38–42, 2009. View at Publisher · View at Google Scholar
  90. J. L. Cadet and C. Brannock, “Invited review Free radicals and the pathobiology of brain dopamine systems,” Neurochemistry International, vol. 32, no. 2, pp. 117–131, 1998. View at Publisher · View at Google Scholar · View at Scopus
  91. L. Zecca, T. Shima, A. Stroppolo et al., “Interaction of neuromelanin and iron in substantia nigra and other areas of human brain,” Neuroscience, vol. 73, no. 2, pp. 407–415, 1996. View at Publisher · View at Google Scholar · View at Scopus
  92. M. Gerlach, K. L. Double, D. Ben-Shachar, L. Zecca, M. B. H. Youdim, and P. Riederer, “Neuromelanin and its interaction with iron as a potential risk factor for dopaminergic neurodegeneration underlying Parkinson's disease,” Neurotoxicity Research, vol. 5, no. 1-2, pp. 35–43, 2003. View at Publisher · View at Google Scholar · View at Scopus
  93. J. M. Gorell, R. J. Ordidge, G. G. Brown, J.-C. Deniau, N. M. Buderer, and J. A. Helpern, “Increased iron-related MRI contrast in the substantia nigra in Parkinson's disease,” Neurology, vol. 45, no. 6, pp. 1138–1143, 1995. View at Publisher · View at Google Scholar · View at Scopus
  94. A. L. Friedlich and M. F. Beal, “Prospects for redox-based therapy in neurodegenerative diseases,” Neurotoxicity Research, vol. 2, no. 2-3, pp. 229–237, 2000. View at Publisher · View at Google Scholar
  95. H. T. Atasoy, O. Nuyan, T. Tunc, M. Yorubulut, A. E. Unal, and L. E. Inan, “T2-weighted MRI in Parkinson's disease; substantia nigra pars compacta hypointensity correlates with the clinical scores,” Neurology India, vol. 52, no. 3, pp. 332–337, 2004. View at Google Scholar · View at Scopus
  96. A. Kikuchi, A. Takeda, H. Onodera et al., “Systemic increase of oxidative nucleic acid damage in Parkinson's disease and multiple system atrophy,” Neurobiology of Disease, vol. 9, no. 2, pp. 244–248, 2002. View at Publisher · View at Google Scholar · View at Scopus
  97. B. A. Faucheux, M.-E. Martin, C. Beaumont, J.-J. Hauw, Y. Agid, and E. C. Hirsch, “Neuromelanin associated redox-active iron is increased in the substantia nigra of patients with Parkinson's disease,” Journal of Neurochemistry, vol. 86, no. 5, pp. 1142–1148, 2003. View at Publisher · View at Google Scholar · View at Scopus
  98. D. T. Dexter, C. J. Carter, F. R. Wells et al., “Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease,” Journal of Neurochemistry, vol. 52, no. 2, pp. 381–389, 1989. View at Publisher · View at Google Scholar · View at Scopus
  99. D. T. Dexter, F. R. Wells, A. J. Lees et al., “Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease,” Journal of Neurochemistry, vol. 52, no. 6, pp. 1830–1836, 1989. View at Publisher · View at Google Scholar · View at Scopus
  100. A. Yoritaka, N. Hattori, K. Uchida, M. Tanaka, E. R. Stadtman, and Y. Mizuno, “Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease,” Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 7, pp. 2696–2701, 1996. View at Publisher · View at Google Scholar · View at Scopus
  101. E. Floor and M. G. Wetzel, “Increased protein oxidation in human substantia nigra pars compacta in comparison with basal ganglia and prefrontal cortex measured with an improved dinitrophenylhydrazine assay,” Journal of Neurochemistry, vol. 70, no. 1, pp. 268–275, 1998. View at Google Scholar · View at Scopus
  102. Y. Ihara, D. Chuda, S. Kuroda, and T. Hayabara, “Hydroxyl radical and superoxide dismutase in blood of patients with Parkinson's disease: relationship to clinical data,” Journal of the Neurological Sciences, vol. 170, no. 2, pp. 90–95, 1999. View at Publisher · View at Google Scholar · View at Scopus
  103. S. Abraham, C. C. Soundararajan, S. Vivekanandhan, and M. Behari, “Erythrocyte antioxidant enzymes in Parkinson's disease,” Indian Journal of Medical Research, vol. 121, no. 2, pp. 111–115, 2005. View at Google Scholar · View at Scopus
  104. C.-M. Chen, J.-L. Liu, Y.-R. Wu et al., “Increased oxidative damage in peripheral blood correlates with severity of Parkinson's disease,” Neurobiology of Disease, vol. 33, no. 3, pp. 429–435, 2009. View at Publisher · View at Google Scholar · View at Scopus
  105. D. W. Dickson, “Linking selective vulnerability to cell death mechanisms in Parkinson's disease,” The American Journal of Pathology, vol. 170, no. 1, pp. 16–19, 2007. View at Publisher · View at Google Scholar · View at Scopus
  106. T. L. Perry, D. V. Godin, and S. Hansen, “Parkinson's disease: a disorder due to nigral glutathione deficiency?” Neuroscience Letters, vol. 33, no. 3, pp. 305–310, 1982. View at Publisher · View at Google Scholar · View at Scopus
  107. E. Sofic, K. W. Lange, K. Jellinger, and P. Riederer, “Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease,” Neuroscience Letters, vol. 142, no. 2, pp. 128–130, 1992. View at Publisher · View at Google Scholar · View at Scopus
  108. V. Dias, E. Junn, and M. M. Mouradian, “The role of oxidative stress in parkinson's disease,” Journal of Parkinson's Disease, vol. 3, no. 4, pp. 461–491, 2013. View at Publisher · View at Google Scholar · View at Scopus
  109. T. L. Perry and V. W. Yong, “Idiopathic Parkinson's disease, progressive supranuclear palsy and glutathione metabolism in the substantia nigra of patients,” Neuroscience Letters, vol. 67, no. 3, pp. 269–274, 1986. View at Publisher · View at Google Scholar · View at Scopus
  110. S. Surendran and S. Rajasankar, “Parkinson's disease: oxidative stress and therapeutic approaches,” Neurological Sciences, vol. 31, no. 5, pp. 531–540, 2010. View at Publisher · View at Google Scholar · View at Scopus
  111. M. F. Beal, “Experimental models of Parkinson's disease,” Nature Reviews Neuroscience, vol. 2, no. 5, pp. 325–332, 2001. View at Publisher · View at Google Scholar · View at Scopus
  112. B. S. Todd, B. Ranjita, K. S. Amy et al., “An in vitro model of Parkinson's disease: linking mitochondrial impairment to altered-synuclein metabolism and oxidative damage,” The Journal of Neuroscience, vol. 22, no. 16, pp. 7006–7015, 2002. View at Google Scholar
  113. R. K. B. Pearce, A. Owen, S. Daniel, P. Jenner, and C. D. Marsden, “Alterations in the distribution of glutathione in the substantia nigra in Parkinson's disease,” Journal of Neural Transmission, vol. 104, no. 6-7, pp. 661–677, 1997. View at Publisher · View at Google Scholar · View at Scopus
  114. J. Weng, M. A. Tikhonova, J. Chen et al., “Ceftriaxone prevents the neurodegeneration and decreased neurogenesis seen in a Parkinson’s disease rat model: an immunohistochemical and MRI study,” Behavioural Brain Research, vol. 305, pp. 126–139, 2016. View at Publisher · View at Google Scholar
  115. D. Sharma, W. Wani, A. Sunkaria et al., “Quercetin attenuates neuronal death against aluminum-induced neurodegeneration in the rat hippocampus,” Neuroscience, vol. 324, pp. 163–176, 2016. View at Publisher · View at Google Scholar
  116. M. R. Saha, P. Dey, S. Begum et al., “Effect of Acacia catechu (L.f.) willd. on oxidative stress with possible implications in alleviating selected cognitive disorders,” PLoS One, vol. 11, no. 3, Article ID e0150574, 2016. View at Publisher · View at Google Scholar
  117. R. Ren, C. Shi, J. Cao et al., “Neuroprotective effects of a standardized flavonoid extract of safflower against neurotoxin-induced cellular and animal models of Parkinson's disease,” Scientific Reports, vol. 6, Article ID 22135, 2016. View at Publisher · View at Google Scholar
  118. N. De Pedro, J. Cantizani, F. J. Ortiz-López et al., “Protective effects of isolecanoric acid on neurodegenerative in vitro models,” Neuropharmacology, vol. 101, pp. 538–548, 2016. View at Publisher · View at Google Scholar · View at Scopus
  119. C.-R. Wu, C.-W. Tsai, S.-W. Chang, C.-Y. Lin, L.-C. Huang, and C.-W. Tsai, “Carnosic acid protects against 6-hydroxydopamine-induced neurotoxicity in in vivo and in vitro model of Parkinson's disease: involvement of antioxidative enzymes induction,” Chemico-Biological Interactions, vol. 225, pp. 40–46, 2015. View at Publisher · View at Google Scholar · View at Scopus
  120. Y. H. Siddique, M. Faisal, F. Naz, S. Jyoti, and Rahul, “Role of Ocimum sanctum leaf extract on dietary supplementation in the transgenic Drosophila model of Parkinson's disease,” Chinese Journal of Natural Medicines, vol. 12, no. 10, pp. 777–781, 2014. View at Publisher · View at Google Scholar · View at Scopus
  121. M. S. Antunes, A. T. R. Goes, S. P. Boeira, M. Prigol, and C. R. Jesse, “Protective effect of hesperidin in a model of Parkinson's disease induced by 6-hydroxydopamine in aged mice,” Nutrition, vol. 30, no. 11-12, pp. 1415–1422, 2014. View at Publisher · View at Google Scholar · View at Scopus
  122. G. Pérez-Barrón, J. G. Ávila-Acevedo, A. M. García-Bores et al., “Neuroprotective effect of Buddleja cordata methanolic extract in the 1-methyl-4-phenylpyridinium Parkinson's disease rat model,” Journal of Natural Medicines, vol. 69, no. 1, pp. 86–93, 2015. View at Publisher · View at Google Scholar · View at Scopus
  123. G. J. Beppe, A. B. Dongmo, H. S. Foyet et al., “Memory-enhancing activities of the aqueous extract of Albizia adianthifolia leaves in the 6-hydroxydopamine-lesion rodent model of Parkinson's disease,” BMC Complementary and Alternative Medicine, vol. 14, article 142, 2014. View at Publisher · View at Google Scholar · View at Scopus
  124. K. Gokul and Muralidhara, “Oral supplements of aqueous extract of tomato seeds alleviate motor abnormality, oxidative impairments and neurotoxicity induced by rotenone in mice: relevance to Parkinson's disease,” Neurochemical Research, vol. 39, no. 7, pp. 1382–1394, 2014. View at Publisher · View at Google Scholar · View at Scopus
  125. Y. H. Siddique, S. Jyoti, and F. Naz, “Effect of epicatechin gallate dietary supplementation on transgenic drosophila model of parkinson's disease,” Journal of Dietary Supplements, vol. 11, no. 2, pp. 121–130, 2014. View at Publisher · View at Google Scholar · View at Scopus
  126. N. Khurana and A. Gajbhiye, “Ameliorative effect of Sida cordifolia in rotenone induced oxidative stress model of Parkinson's disease,” NeuroToxicology, vol. 39, pp. 57–64, 2013. View at Publisher · View at Google Scholar · View at Scopus
  127. G. Chandran and M. Muralidhara, “Neuroprotective effect of aqueous extract of selaginella delicatula as evidenced by abrogation of rotenone-induced motor deficits, oxidative dysfunctions, and neurotoxicity in mice,” Cellular and Molecular Neurobiology, vol. 33, no. 7, pp. 929–942, 2013. View at Publisher · View at Google Scholar · View at Scopus
  128. J. Prakash, S. K. Yadav, S. Chouhan, and S. P. Singh, “Neuroprotective role of withania somnifera root extract in maneb-paraquat induced mouse model of parkinsonism,” Neurochemical Research, vol. 38, no. 5, pp. 972–980, 2013. View at Publisher · View at Google Scholar · View at Scopus
  129. M. T. Mansouri, Y. Farbood, M. J. Sameri, A. Sarkaki, B. Naghizadeh, and M. Rafeirad, “Neuroprotective effects of oral gallic acid against oxidative stress induced by 6-hydroxydopamine in rats,” Food Chemistry, vol. 138, no. 2-3, pp. 1028–1033, 2013. View at Publisher · View at Google Scholar · View at Scopus
  130. M. H. Shalavadi, V. M. Chandrashekhar, S. P. Avinash, C. Sowmya, and A. Ramkishan, “Neuroprotective activity of Stereospermum suaveolens DC against 6-OHDA induced Parkinson's disease model,” Indian Journal of Pharmacology, vol. 44, no. 6, pp. 737–743, 2012. View at Publisher · View at Google Scholar · View at Scopus
  131. S.-M. Liu, X.-Z. Li, Y. Huo, and F. Lu, “Protective effect of extract of Acanthopanax senticosus harms on dopaminergic neurons in Parkinson's disease mice,” Phytomedicine, vol. 19, no. 7, pp. 631–638, 2012. View at Publisher · View at Google Scholar · View at Scopus
  132. A. Anandhan, K. Tamilselvam, T. Radhiga, S. Rao, M. M. Essa, and T. Manivasagam, “Theaflavin, a black tea polyphenol, protects nigral dopaminergic neurons against chronic MPTP/probenecid induced Parkinson's disease,” Brain Research, vol. 1433, pp. 104–113, 2012. View at Publisher · View at Google Scholar · View at Scopus
  133. J. Nataraj, T. Manivasagam, A. J. Thenmozhi, and M. M. Essa, “Lutein protects dopaminergic neurons against MPTP-induced apoptotic death and motor dysfunction by ameliorating mitochondrial disruption and oxidative stress,” Nutritional Neuroscience, vol. 19, no. 6, pp. 237–246, 2016. View at Publisher · View at Google Scholar
  134. J. Nataraj, T. Manivasagam, A. Justin Thenmozhi, and M. M. Essa, “Neuroprotective effect of asiatic acid on rotenone-induced mitochondrial dysfunction and oxidative stress-mediated apoptosis in differentiated SH-SYS5Y cells,” Nutritional Neuroscience, 2016. View at Publisher · View at Google Scholar
  135. C. Dhanalakshmi, T. Manivasagam, J. Nataraj, A. Justin Thenmozhi, and M. M. Essa, “Neurosupportive role of vanillin, a natural phenolic compound, on rotenone induced neurotoxicity in SH-SY5Y neuroblastoma cells,” Evidence-Based Complementary and Alternative Medicine, vol. 2015, Article ID 626028, 11 pages, 2015. View at Publisher · View at Google Scholar · View at Scopus
  136. K. Tamilselvam, N. Braidy, T. Manivasagam et al., “Neuroprotective effects of hesperidin, a plant flavanone, on rotenone-induced oxidative stress and apoptosis in a cellular model for Parkinson's disease,” Oxidative Medicine and Cellular Longevity, vol. 2013, Article ID 102741, 11 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  137. N. Braidy, S. Selvaraju, M. M. Essa et al., “Neuroprotective effects of a variety of pomegranate juice extracts against MPTP-induced cytotoxicity and oxidative stress in human primary neurons,” Oxidative Medicine and Cellular Longevity, vol. 2013, Article ID 685909, 12 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  138. S. Ahmad, M. B. Khan, M. N. Hoda et al., “Neuroprotective effect of sesame seed oil in 6-hydroxydopamine induced neurotoxicity in mice model: cellular, biochemical and neurochemical evidence,” Neurochemical Research, vol. 37, no. 3, pp. 516–526, 2012. View at Publisher · View at Google Scholar · View at Scopus
  139. E. N. Martins, N. T. C. Pessano, L. Leal et al., “Protective effect of Melissa officinalis aqueous extract against Mn-induced oxidative stress in chronically exposed mice,” Brain Research Bulletin, vol. 87, no. 1, pp. 74–79, 2012. View at Publisher · View at Google Scholar · View at Scopus
  140. L. Hritcu, H. S. Foyet, M. Stefan, M. Mihasan, A. E. Asongalem, and P. Kamtchouing, “Neuroprotective effect of the methanolic extract of Hibiscus asper leaves in 6-hydroxydopamine-lesioned rat model of Parkinson's disease,” Journal of Ethnopharmacology, vol. 137, no. 1, pp. 585–591, 2011. View at Publisher · View at Google Scholar · View at Scopus
  141. V. L. Ranpariya, S. K. Parmar, N. R. Sheth, and V. M. Chandrashekhar, “Neuroprotective activity of Matricaria recutita against fluoride-induced stress in rats,” Pharmaceutical Biology, vol. 49, no. 7, pp. 696–701, 2011. View at Publisher · View at Google Scholar · View at Scopus
  142. Y. Wang, H. Xu, Q. Fu, R. Ma, and J. Xiang, “Protective effect of resveratrol derived from Polygonum cuspidatum and its liposomal form on nigral cells in Parkinsonian rats,” Journal of the Neurological Sciences, vol. 304, no. 1-2, pp. 29–34, 2011. View at Publisher · View at Google Scholar · View at Scopus
  143. R. Verma and B. Nehru, “Effect of centrophenoxine against rotenone-induced oxidative stress in an animal model of Parkinson's disease,” Neurochemistry International, vol. 55, no. 6, pp. 369–375, 2009. View at Publisher · View at Google Scholar · View at Scopus
  144. H. Kaur, S. Chauhan, and R. Sandhir, “Protective effect of lycopene on oxidative stress and cognitive decline in rotenone induced model of Parkinson's disease,” Neurochemical Research, vol. 36, no. 8, pp. 1435–1443, 2011. View at Publisher · View at Google Scholar · View at Scopus
  145. M. M. Khan, S. S. Raza, H. Javed et al., “Rutin protects dopaminergic neurons from oxidative stress in an animal model of Parkinson's disease,” Neurotoxicity Research, vol. 22, no. 1, pp. 1–15, 2012. View at Publisher · View at Google Scholar · View at Scopus
  146. M. M. Essa, S. Subash, C. Dhanalakshmi et al., “Dietary supplementation of walnut partially reverses 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine induced neurodegeneration in a mouse model of Parkinson's disease,” Neurochemical Research, vol. 40, no. 6, pp. 1283–1293, 2015. View at Publisher · View at Google Scholar · View at Scopus
  147. S. R. Jahromi, M. Haddadi, T. Shivanandappa, and S. R. Ramesh, “Modulatory effect of Decalepis hamiltonii on ethanol-induced toxicity in transgenic Drosophila model of Parkinson's disease,” Neurochemistry International, vol. 80, pp. 1–6, 2015. View at Publisher · View at Google Scholar · View at Scopus
  148. Y.-T. Tseng, F.-R. Chang, and Y.-C. Lo, “The Chinese herbal formula Liuwei dihuang protects dopaminergic neurons against Parkinson's toxin through enhancing antioxidative defense and preventing apoptotic death,” Phytomedicine, vol. 21, no. 5, pp. 724–733, 2014. View at Publisher · View at Google Scholar · View at Scopus
  149. B. Guo, D. Xu, H. Duan et al., “Therapeutic effects of multifunctional tetramethylpyrazine nitrone on models of Parkinson's disease in vitro and in vivo,” Biological and Pharmaceutical Bulletin, vol. 37, no. 2, pp. 274–285, 2014. View at Publisher · View at Google Scholar · View at Scopus
  150. J. H. Sudati, F. A. Vieira, S. S. Pavin et al., “Valeriana officinalis attenuates the rotenone-induced toxicity in drosophila melanogaster,” NeuroToxicology, vol. 37, pp. 118–126, 2013. View at Publisher · View at Google Scholar · View at Scopus
  151. H. Pasban-Aliabadi, S. Esmaeili-Mahani, V. Sheibani, M. Abbasnejad, A. Mehdizadeh, and M. M. Yaghoobi, “Inhibition of 6-hydroxydopamine-induced PC12 cell apoptosis by olive (Olea europaea L.) leaf extract is performed by its main component oleuropein,” Rejuvenation Research, vol. 16, no. 2, pp. 134–142, 2013. View at Publisher · View at Google Scholar · View at Scopus
  152. K.-H. Kim, K. Song, S.-H. Yoon, O. Shehzad, Y.-S. Kim, and J. H. Son, “Rescue of PINK1 protein null-specific mitochondrial complex IV deficits by ginsenoside Re activation of nitric oxide signaling,” The Journal of Biological Chemistry, vol. 287, no. 53, pp. 44109–44120, 2012. View at Publisher · View at Google Scholar · View at Scopus
  153. S. Li and X.-P. Pu, “Neuroprotective effect of kaempferol against a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced mouse model of Parkinson's disease,” Biological and Pharmaceutical Bulletin, vol. 34, no. 8, pp. 1291–1296, 2011. View at Publisher · View at Google Scholar · View at Scopus
  154. Z. Liang, F. Shi, Y. Wang et al., “Neuroprotective effects of tenuigenin in a SH-SY5Y cell model with 6-OHDA-induced injury,” Neuroscience Letters, vol. 497, no. 2, pp. 104–109, 2011. View at Publisher · View at Google Scholar · View at Scopus
  155. S. Hu, R. Han, S. Mak, and Y. Han, “Protection against 1-methyl-4-phenylpyridinium ion (MPP+)-induced apoptosis by water extract of ginseng (Panax ginseng C.A. Meyer) in SH-SY5Y cells,” Journal of Ethnopharmacology, vol. 135, no. 1, pp. 34–42, 2011. View at Publisher · View at Google Scholar · View at Scopus
  156. J. G. Choi, H. G. Kim, M. C. Kim et al., “Polygalae radix inhibits toxin-induced neuronal death in the Parkinson's disease models,” Journal of Ethnopharmacology, vol. 134, no. 2, pp. 414–421, 2011. View at Publisher · View at Google Scholar · View at Scopus
  157. T. Sengupta, J. Vinayagam, N. Nagashayana, B. Gowda, P. Jaisankar, and K. P. Mohanakumar, “Antiparkinsonian effects of aqueous methanolic extract of Hyoscyamus niger seeds result from its monoamine oxidase inhibitory and hydroxyl radical scavenging potency,” Neurochemical Research, vol. 36, no. 1, pp. 177–186, 2011. View at Publisher · View at Google Scholar · View at Scopus
  158. L. An, S. Liu, Y. Dong, B. Tang, and W. Dong, “Protective effect of effective part of Acanthopanacis senticosus on damage of PC12 cells induced by MPP+,” Zhongguo Zhongyao Zazhi, vol. 35, no. 15, pp. 2021–2026, 2010. View at Publisher · View at Google Scholar · View at Scopus
  159. H. G. Kim, M. S. Ju, D.-H. Kim et al., “Protective effects of Chunghyuldan against ROS-mediated neuronal cell death in models of Parkinson's disease,” Basic & Clinical Pharmacology & Toxicology, vol. 107, no. 6, pp. 958–964, 2010. View at Publisher · View at Google Scholar
  160. C.-H. Lee, D.-S. Hwang, H. G. Kim et al., “Protective effect of Cyperi Rhizoma against 6-hydroxydopamine-induced neuronal damage,” Journal of Medicinal Food, vol. 13, no. 3, pp. 564–571, 2010. View at Publisher · View at Google Scholar · View at Scopus
  161. D. Shu, J. He, and J. Chen, “Neuroprotective effects and mechanisms of Chuanxiong Chatiao pulvis against MPTP-induced dopaminergic neurotoxicity in mice model of parkinson's disease,” Zhongguo Zhongyao Zazhi, vol. 34, no. 19, pp. 2494–2497, 2009. View at Google Scholar · View at Scopus
  162. J. S. Shim, H. G. Kim, M. S. Ju, J. G. Choi, S. Y. Jeong, and M. S. Oh, “Effects of the hook of Uncaria rhynchophylla on neurotoxicity in the 6-hydroxydopamine model of Parkinson's disease,” Journal of Ethnopharmacology, vol. 126, no. 2, pp. 361–365, 2009. View at Publisher · View at Google Scholar · View at Scopus
  163. S. R. Sankar, T. Manivasagam, A. Krishnamurti, and M. Ramanathan, “The neuroprotective effect of Withania somnifera root extract in MPTP-intoxicated mice: an analysis of behavioral and biochemical varibles,” Cellular and Molecular Biology Letters, vol. 12, no. 4, pp. 473–481, 2007. View at Publisher · View at Google Scholar · View at Scopus
  164. M. Ahmad, S. Yousuf, M. B. Khan et al., “Protective effects of ethanolic extract of Delphinium denudatum in a rat model of Parkinson's disease,” Human and Experimental Toxicology, vol. 25, no. 7, pp. 361–368, 2006. View at Publisher · View at Google Scholar · View at Scopus
  165. M. Ahmad, S. Yousuf, M. B. Khan et al., “Attenuation by Nardostachys jatamansi of 6-hydroxydopamine-induced parkinsonism in rats: behavioral, neurochemical, and immunohistochemical studies,” Pharmacology Biochemistry and Behavior, vol. 83, no. 1, pp. 150–160, 2006. View at Publisher · View at Google Scholar · View at Scopus
  166. S. Zhang, S.-Y. Shao, X.-Y. Song et al., “Protective effects of Forsythia suspense extract with antioxidant and anti-inflammatory properties in a model of rotenone induced neurotoxicity,” NeuroToxicology, vol. 52, pp. 72–83, 2016. View at Publisher · View at Google Scholar · View at Scopus
  167. K.-T. Lu, M.-C. Ko, B.-Y. Chen et al., “Neuroprotective effects of resveratrol on MPTP-induced neuron loss mediated by free radical scavenging,” Journal of Agricultural and Food Chemistry, vol. 56, no. 16, pp. 6910–6913, 2008. View at Publisher · View at Google Scholar · View at Scopus
  168. R. B. Mythri and M. M. Srinivas Bharath, “Curcumin: a potential neuroprotective agent in Parkinson's disease,” Current Pharmaceutical Design, vol. 18, no. 1, pp. 91–99, 2012. View at Publisher · View at Google Scholar · View at Scopus
  169. W. J. Szlachcic, P. M. Switonski, W. J. Krzyzosiak, M. Figlerowicz, and M. Figiel, “Huntington disease iPSCs show early molecular changes in intracellular signaling, the expression of oxidative stress proteins and the p53 pathway,” DMM Disease Models and Mechanisms, vol. 8, no. 9, pp. 1047–1057, 2015. View at Publisher · View at Google Scholar · View at Scopus
  170. X. Li, A. Valencia, E. Sapp et al., “Aberrant Rab11-dependent trafficking of the neuronal glutamate transporter EAAC1 causes oxidative stress and cell death in Huntington's disease,” Journal of Neuroscience, vol. 30, no. 13, pp. 4552–4561, 2010. View at Publisher · View at Google Scholar · View at Scopus
  171. Y. Sari, “Huntington's disease: from mutant huntingtin protein to neurotrophic factor therapy,” International Journal of Biomedical Science, vol. 7, no. 2, pp. 89–100, 2011. View at Google Scholar · View at Scopus
  172. F. O. Walker, “Huntington's disease,” Lancet, vol. 369, no. 9557, pp. 218–228, 2007. View at Publisher · View at Google Scholar · View at Scopus
  173. B. Rotblat, A. L. Southwell, D. E. Ehrnhoefer et al., “HACE1 reduces oxidative stress and mutant Huntingtin toxicity by promoting the NRF2 response,” Proceedings of the National Academy of Sciences of the United States of America, vol. 111, no. 8, pp. 3032–3037, 2014. View at Publisher · View at Google Scholar · View at Scopus
  174. A. Johri and M. F. Beal, “Antioxidants in Huntington's disease,” Biochimica et Biophysica Acta, vol. 1822, no. 5, pp. 664–674, 2012. View at Publisher · View at Google Scholar · View at Scopus
  175. E. Trushina and C. T. McMurray, “Oxidative stress and mitochondrial dysfunction in neurodegenerative diseases,” Neuroscience, vol. 145, no. 4, pp. 1233–1248, 2007. View at Publisher · View at Google Scholar · View at Scopus
  176. L. M. Sayre, G. Perry, and M. A. Smith, “Oxidative stress and neurotoxicity,” Chemical Research in Toxicology, vol. 21, no. 1, pp. 172–188, 2008. View at Publisher · View at Google Scholar · View at Scopus
  177. D.-H. Lee, R. Gold, and R. A. Linker, “Mechanisms of oxidative damage in multiple sclerosis and neurodegenerative diseases: therapeutic modulation via fumaric acid esters,” International Journal of Molecular Sciences, vol. 13, no. 9, pp. 11783–11803, 2012. View at Publisher · View at Google Scholar · View at Scopus
  178. C.-M. Chen, Y.-R. Wu, M.-L. Cheng et al., “Increased oxidative damage and mitochondrial abnormalities in the peripheral blood of Huntington's disease patients,” Biochemical and Biophysical Research Communications, vol. 359, no. 2, pp. 335–340, 2007. View at Publisher · View at Google Scholar · View at Scopus
  179. S. Choudhary, P. Kumar, and J. Malik, “Plants and phytochemicals for Huntington′s disease,” Pharmacognosy Reviews, vol. 7, no. 14, pp. 81–91, 2013. View at Publisher · View at Google Scholar · View at Scopus
  180. M. Gu, M. T. Gash, V. M. Mann, F. Javoy-Agid, J. M. Cooper, and A. H. V. Schapira, “Mitochondrial defect in Huntington's disease caudate nucleus,” Annals of Neurology, vol. 39, no. 3, pp. 385–389, 1996. View at Publisher · View at Google Scholar · View at Scopus
  181. I. Túnez, F. Sánchez-López, E. Agüera, R. Fernández-Bolaños, F. M. Sánchez, and I. Tasset-Cuevas, “Important role of oxidative stress biomarkers in Huntington's disease,” Journal of Medicinal Chemistry, vol. 54, no. 15, pp. 5602–5606, 2011. View at Publisher · View at Google Scholar
  182. N. Klepac, M. Relja, R. Klepac, S. Hećimović, T. Babić, and V. Trkulja, “Oxidative stress parameters in plasma of Huntington's disease patients, asymptomatic Huntington's disease gene carriers and healthy subjects: a cross-sectional study,” Journal of Neurology, vol. 254, no. 12, pp. 1676–1683, 2007. View at Publisher · View at Google Scholar · View at Scopus
  183. A.-V. Goula, B. R. Berquist, D. M. Wilson III, V. C. Wheeler, Y. Trottier, and K. Merienne, “Stoichiometry of base excision repair proteins correlates with increased somatic CAG instability in striatum over cerebellum in Huntington's disease transgenic mice,” PLoS Genetics, vol. 5, no. 12, Article ID e1000749, 2009. View at Publisher · View at Google Scholar · View at Scopus
  184. S. E. Browne, A. C. Bowling, U. MacGarvey et al., “Oxidative damage and metabolic dysfunction in huntington's disease: selective vulnerability of the basal ganglia,” Annals of Neurology, vol. 41, no. 5, pp. 646–653, 1997. View at Publisher · View at Google Scholar · View at Scopus
  185. M. Ribeiro, T. R. Rosenstock, T. Cunha-Oliveira, I. L. Ferreira, C. R. Oliveira, and A. C. Rego, “Glutathione redox cycle dysregulation in Huntington's disease knock-in striatal cells,” Free Radical Biology and Medicine, vol. 53, no. 10, pp. 1857–1867, 2012. View at Publisher · View at Google Scholar · View at Scopus
  186. N. Stoy, G. M. Mackay, C. M. Forrest et al., “Tryptophan metabolism and oxidative stress in patients with Huntington's disease,” Journal of Neurochemistry, vol. 93, no. 3, pp. 611–623, 2005. View at Publisher · View at Google Scholar · View at Scopus
  187. R. Duran, F. J. Barrero, B. Morales, J. D. Luna, M. Ramirez, and F. Vives, “Oxidative stress and plasma aminopeptidase activity in Huntington's disease,” Journal of Neural Transmission, vol. 117, no. 3, pp. 325–332, 2010. View at Publisher · View at Google Scholar · View at Scopus
  188. A. M. Oliveira, S. M. Cardoso, M. Ribeiro, R. S. G. R. Seixas, A. M. S. Silva, and A. C. Rego, “Protective effects of 3-alkyl luteolin derivatives are mediated by Nrf2 transcriptional activity and decreased oxidative stress in Huntington's disease mouse striatal cells,” Neurochemistry International, vol. 91, pp. 1–12, 2015. View at Publisher · View at Google Scholar · View at Scopus
  189. B. D. Shivasharan, P. Nagakannan, B. S. Thippeswamy, V. P. Veerapur, P. Bansal, and M. K. Unnikrishnan, “Protective effect of Calendula officinalis Linn. flowers against 3-nitropropionic acid induced experimental Huntington's disease in rats,” Drug and Chemical Toxicology, vol. 36, no. 4, pp. 466–473, 2013. View at Publisher · View at Google Scholar · View at Scopus
  190. H. M. Mahdy, M. G. Tadros, M. R. Mohamed, A. M. Karim, and A. E. Khalifa, “The effect of Ginkgo biloba extract on 3-nitropropionic acid-induced neurotoxicity in rats,” Neurochemistry International, vol. 59, no. 6, pp. 770–778, 2011. View at Publisher · View at Google Scholar · View at Scopus
  191. I. Tasset, A. J. Pontes, A. J. Hinojosa, R. de la Torre, and I. Túnez, “Olive oil reduces oxidative damage in a 3-nitropropionic acid-induced huntington's disease-like rat model,” Nutritional Neuroscience, vol. 14, no. 3, pp. 106–111, 2011. View at Publisher · View at Google Scholar · View at Scopus
  192. O. Sagredo, M. R. Pazos, V. Satta, J. A. Ramos, R. G. Pertwee, and J. Fernández-Ruiz, “Neuroprotective effects of phytocannabinoid-based medicines in experimental models of Huntington's disease,” Journal of Neuroscience Research, vol. 89, no. 9, pp. 1509–1518, 2011. View at Publisher · View at Google Scholar · View at Scopus
  193. Y. Gao, S.-F. Chu, J.-P. Li et al., “Protopanaxtriol protects against 3-nitropropionic acid-induced oxidative stress in a rat model of Huntington's disease,” Acta Pharmacologica Sinica, vol. 36, no. 3, pp. 311–322, 2015. View at Publisher · View at Google Scholar · View at Scopus
  194. I. Túnez, P. Montilla, M. Del Carmen Muñoz, M. Feijóo, and M. Salcedo, “Protective effect of melatonin on 3-nitropropionic acid-induced oxidative stress in synaptosomes in an animal model of Huntington's disease,” Journal of Pineal Research, vol. 37, no. 4, pp. 252–256, 2004. View at Publisher · View at Google Scholar
  195. H. I. Rocha-González, M. Ambriz-Tututi, and V. Granados-Soto, “Resveratrol: a natural compound with pharmacological potential in neurodegenerative diseases,” CNS Neuroscience and Therapeutics, vol. 14, no. 3, pp. 234–247, 2008. View at Publisher · View at Google Scholar · View at Scopus
  196. O. A. Andreassen, R. J. Ferrante, A. Dedeoglu, and M. F. Beal, “Lipoic acid improves survival in transgenic mouse models of Huntington's disease,” NeuroReport, vol. 12, no. 15, pp. 3371–3373, 2001. View at Publisher · View at Google Scholar · View at Scopus
  197. D. E. Ehrnhoefer, M. Duennwald, P. Markovic et al., “Green tea (-)-epigallocatechin-gallate modulates early events in huntingtin misfolding and reduces toxicity in Huntington's disease models,” Human Molecular Genetics, vol. 15, no. 18, pp. 2743–2751, 2006. View at Publisher · View at Google Scholar · View at Scopus
  198. K. M. Denny Joseph and Muralidhara, “Enhanced neuroprotective effect of fish oil in combination with quercetin against 3-nitropropionic acid induced oxidative stress in rat brain,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 40, no. 1, pp. 83–92, 2013. View at Publisher · View at Google Scholar · View at Scopus
  199. J. Fu, J. Jin, R. H. Cichewicz et al., “Trans-(-)-ε-viniferin increases mitochondrial sirtuin 3 (SIRT3), activates AMP-activated protein kinase (AMPK), and protects cells in models of huntington disease,” Journal of Biological Chemistry, vol. 287, no. 29, pp. 24460–24472, 2012. View at Publisher · View at Google Scholar · View at Scopus
  200. N. Huang, J. Lin, J. Lin et al., “A new drug design targeting the adenosinergic system for Huntington's disease,” PLoS ONE, vol. 6, no. 6, Article ID 20934, 2011. View at Publisher · View at Google Scholar
  201. V. L. Ranpariya, S. K. Parmar, N. R. Sheth, and V. M. Chandrashekhar, “Neuroprotective activity of Matricaria recutita against fluoride-induced stress in rats,” Pharmaceutical Biology, vol. 49, no. 7, pp. 696–701, 2011. View at Publisher · View at Google Scholar · View at Scopus
  202. P. Kumar and A. Kumar, “Possible neuroprotective effect of withania somnifera root extract against 3-Nitropropionic acid-induced behavioral, biochemical, and mitochondrial dysfunction in an animal model of huntington's disease,” Journal of Medicinal Food, vol. 12, no. 3, pp. 591–600, 2009. View at Publisher · View at Google Scholar · View at Scopus
  203. G. K. Shinomol and Muralidhara, “Prophylactic neuroprotective property of Centella asiatica against 3-nitropropionic acid induced oxidative stress and mitochondrial dysfunctions in brain regions of prepubertal mice,” NeuroToxicology, vol. 29, no. 6, pp. 948–957, 2008. View at Publisher · View at Google Scholar · View at Scopus
  204. M. Kaur, A. Prakash, and A. N. Kalia, “Neuroprotective potential of antioxidant potent fractions from Convolvulus pluricaulis Chois. in 3-nitropropionic acid challenged rats,” Nutritional Neuroscience, vol. 19, no. 2, pp. 70–78, 2016. View at Publisher · View at Google Scholar
  205. B. N. Al-Sabahi, M. O. Fatope, M. M. Essa et al., “Pomegranate seed oil: effect on 3-nitropropionic acid-induced neurotoxicity in PC12 cells and elucidation of unsaturated fatty acids composition,” Nutritional Neuroscience, vol. 20, no. 1, pp. 40–48, 2017. View at Publisher · View at Google Scholar